Short answer
Twist Bioscience Corp (TWST) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 fiscal 2026 results for quarter ended June 30, 2026.
Twist Bioscience Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 fiscal 2026 results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the financial results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q3 FY26 revenue $118.4M, up 23% YoY; 14th consecutive quarter of sequential growth
- DSPS revenue $56.6M, up 39%; NGS revenue $61.8M, up 12%, indicating stronger synthesis momentum
- Gross margin 52.8%, up 120 basis points sequentially, while adjusted EBITDA loss widened to $11.3M
- FY26 revenue guidance raised to $456–$457M; Q4 guidance implies $123–$124M revenue and adjusted EBITDA breakeven
- Cash, cash equivalents and short-term investments approximately $167M at June 30, 2026; net loss $35.1M included no prior-year spinout gain
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Twist Bioscience Corp 8-K filings
Get the next TWST 8-K as it lands
Follow TWST for push alerts, or ask the research agent what this filing means.